{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:39:31Z","timestamp":1786700371293,"version":"build-2736575974"},"reference-count":94,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14712598.2026.2706715","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:21:36Z","timestamp":1784301696000},"page":"677-691","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer"],"prefix":"10.1080","volume":"26","author":[{"given":"Yunqi","family":"Mi","sequence":"first","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Ding","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052049"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14050442"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.01.003"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113328"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321555"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2025.195"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_5_14_1","unstructured":"Phase 1b multicenter Open-label study of Datopotamab deruxtecan (dato-DXd) in combination with Pembrolizumab with or without platinum chemotherapy in subjects with advanced or metastatic non-small cell lung cancer (TROPION-Lung02). Internet. 2020 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04526691"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9004"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0230"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2409621"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03883-5"},{"key":"e_1_3_5_19_1","unstructured":"A randomized Open-label multicenter Phase III clinical study of SKB264 in combination with Pembrolizumab versus Pembrolizumab as first-line treatment for PD-L1 positive patients with locally advanced or metastatic non-small cell lung cancer [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06448312"},{"key":"e_1_3_5_20_1","unstructured":"A randomized Open-label multicenter Phase III clinical study of SKB264 in combination with Pembrolizumab versus chemotherapy in combination with Pembrolizumab as first-line treatment for PD-L1 negative patients with locally advanced or metastatic non-squamous non-small cell lung cancer [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06711900"},{"key":"e_1_3_5_21_1","unstructured":"A randomized Open-label Phase 3 study of MK-2870 in combination with Pembrolizumab compared to Pembrolizumab monotherapy in the first-line treatment of participants with metastatic non-small cell lung cancer with PD-L1 TPS Greater than or equal to 50% (TroFuse-007) [Internet]. 2023 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06170788"},{"key":"e_1_3_5_22_1","unstructured":"A Phase Ib\/II Open-label multicenter randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic non-small cell lung cancer (morpheus-lung) [Internet]. 2017 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03337698"},{"key":"e_1_3_5_23_1","unstructured":"An Open-label multicenter Phase 3 randomized active-comparator-controlled clinical study of Pembrolizumab (MK-3475) in combination with Sacituzumab govitecan versus MK-3475 monotherapy as first-line treatment in participants with PD L1 TPS greater than or equal to 50% metastatic non-small cell lung cancer (KEYNOTE D46\/EVOKE-03). Internet. 2022 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05609968"},{"key":"e_1_3_5_24_1","unstructured":"An Open-label multicenter Phase 2 study of Sacituzumab govitecan combinations in first-line treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations [Internet]. 2021 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05186974"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.10.016"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70060"},{"key":"e_1_3_5_27_1","unstructured":"A Phase III clinical trial of adjuvant treatment with Sacituzumab and zimberelimab for stage IB-IIIA-IIIB(N2) Previously resected (R0) non-small cell lung cancer patients that did not achieve pathological complete response after neoadjuvant treatment_arian [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06431633"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-359"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194926"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3563"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13378"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221575"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.014"},{"key":"e_1_3_5_37_1","unstructured":"A Phase III Open-label randomised study of osimertinib with or without Datopotamab deruxtecan (dato-DXd) as first-line treatment in participants with epidermal growth factor receptor (EGFR) mutation-positive locally advanced or metastatic non-small cell lung cancer [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06350097"},{"key":"e_1_3_5_38_1","unstructured":"A Phase III Open-label sponsor-blind randomized study of Dato-DXd with or without osimertinib versus platinum-based doublet chemotherapy for participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer whose disease has progressed on prior osimertinib treatment (TROPION-Lung15) [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06417814"},{"key":"e_1_3_5_39_1","unstructured":"A randomized Open-label multicenter Phase III clinical study of SKB264 in combination with osimertinib versus osimertinib alone as first-line treatment for patients with epidermal growth factor receptor (EGFR) mutations locally advanced or metastatic non-squamous non-small cell lung cancer [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06670196"},{"key":"e_1_3_5_40_1","unstructured":"A multicenter single-arm Phase II clinical study of Sacituzumab tirumotecan in combination with furmonertinib as second-line treatment for EGFR-mutant advanced or metastatic NSCLC after failure of first-line third-generation EGFR-TKI therapy [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07193160"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8521"},{"key":"e_1_3_5_42_1","unstructured":"A Phase III randomised Open-label global study of Datopotamab deruxtecan (dato-DXd) in combination with Rilvegostomig or Rilvegostomig monotherapy versus Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC \u2265 50%) and without actionable genomic alterations (TROPION-Lung10) [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06357533"},{"key":"e_1_3_5_43_1","unstructured":"A Phase III randomised Open-label global study of adjuvant Datopotamab deruxtecan (dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care following complete tumour resection in participants with stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (TROPION-Lung12) [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06564844"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30122645"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4277-x"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-968"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.1361"},{"key":"e_1_3_5_49_1","unstructured":"Disitamab vedotin in combination with tislelizumab and Bevacizumab in a Phase II clinical study of locally advanced or metastatic non-small cell lung cancer with HER2 mutation\/amplification\/expression [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06749860"},{"key":"e_1_3_5_50_1","unstructured":"A prospective single-arm multicenter Phase II clinical study on envafolimab combined with Disitamab vedotin and carboplatin for resectable stage II-III HER2-mutant non-small cell lung cancer [Internet]. 2024 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06734182"},{"key":"e_1_3_5_51_1","unstructured":"A Phase Ib multicenter Open-label study to evaluate the safety and tolerability of Trastuzumab deruxtecan (T-DXd) and immunotherapy agents with and without chemotherapy agents in first-line treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and human epidermal growth factor receptor 2 (HER2) overexpression (OE) (DESTINY-Lung03) [Internet]. 2020 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04686305"},{"key":"e_1_3_5_52_1","unstructured":"A Phase 1b multicenter two-part Open-label study of Trastuzumab deruxtecan (DS-8201a) an anti-human epidermal growth factor receptor-2 (HER2)-antibody drug conjugate (ADC) in combination with Pembrolizumab an anti-PD-1 antibody for subjects with locally advanced\/metastatic breast or non-small cell lung cancer (NSCLC) [Internet]. 2019 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04042701"},{"key":"e_1_3_5_53_1","unstructured":"A Phase 3 multicenter randomized Open-label trial of Trastuzumab deruxtecan in combination with Pembrolizumab versus platinum-based chemotherapy in combination with Pembrolizumab as first-line therapy in participants with locally advanced unresectable or metastatic HER2 overexpressing and PD-L1 TPS <50% non-squamous non-small cell lung cancer (DESTINY-Lung06) [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06899126"},{"key":"e_1_3_5_54_1","unstructured":"An Open-label single-center Phase Ib\/II study to evaluate the safety efficacy and pharmacokinetics of RC48-ADC combined with pyrotinib in local advanced or metastasis NSCLC with HER2 mutation [Internet]. 2023 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05745740"},{"key":"e_1_3_5_55_1","unstructured":"Phase IB\/II clinical study of the safety tolerability pharmacokinetics and efficacy of injectable SHR-A1811 in combination with pyrotinib or SHR-1316 in subjects with advanced non-small cell lung cancer with HER2 [Internet]. 2022 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05482568"},{"key":"e_1_3_5_56_1","unstructured":"A Phase I\/II study evaluating the safety tolerability and efficacy of sotorasib plus Trastuzumab deruxtecan in patients with advanced non-small cell lung cancer with a KRASG12C mutation [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07012031"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.01.009"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01279-8"},{"key":"e_1_3_5_59_1","unstructured":"A Phase I multicenter Open-label first-in-human dose escalation and expansion study of AZD9592 as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors [Internet]. 2022 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05647122"},{"key":"e_1_3_5_60_1","unstructured":"A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with osimertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer [Internet]. 2023 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05880706"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.064"},{"key":"e_1_3_5_62_1","unstructured":"Evaluation of JSKN016 combination therapy in subjects with advanced non-small cell lung cancer: a Phase Ib study [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06868732"},{"key":"e_1_3_5_63_1","unstructured":"A Phase Ib\/II multi-site Open-label two-part trial to evaluate the efficacy safety pharmacokinetics and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06892548"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0517-4"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.003"},{"key":"e_1_3_5_66_1","unstructured":"A Phase 1 Open-label study of HER3-DXd (patritumab deruxtecan; U3-1402) in combination with osimertinib in subjects with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) [Internet]. 2020 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04676477"},{"key":"e_1_3_5_67_1","unstructured":"A Phase Ib\/II multi-site Open-label dose finding trial to evaluate the safety efficacy and pharmacokinetics of BNT326 in combination with BNT327 in participants with advanced non-small cell lung cancer (NSCLC) [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07111520"},{"key":"e_1_3_5_68_1","unstructured":"Open-label Phase 2 study of Tusamitamab Ravtansine (SAR408701) combined with Pembrolizumab and Tusamitamab Ravtansine (SAR408701) combined with Pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with CEACAM5 positive expression advanced\/metastatic non-squamous non-small-cell lung cancer (NSQ NSCLC) [Internet]. 2020 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04524689"},{"key":"e_1_3_5_69_1","unstructured":"Open-label single-arm trial to evaluate antitumor activity safety and pharmacokinetics of Tusamitamab Ravtansine (SAR408701) used in combination with Ramucirumab or Ramucirumab and Pembrolizumab in metastatic non-squamous non small-cell lung cancer (NSQ NSCLC) patients with CEACAM5-positive tumors Previously treated with platinum-based chemotherapy and an immune checkpoint inhibitor [Internet]. 2020 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04394624."},{"key":"e_1_3_5_70_1","unstructured":"A multicenter Phase 1\/1b Open-label dose-escalation study of ABBV-399 an antibody drug conjugate in subjects with advanced solid tumors [Internet]. 2014 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02099058"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00739"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.001"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100262"},{"key":"e_1_3_5_74_1","unstructured":"A randomized Open controlled multicenter Phase II clinical study of RC108 in combination with furmonertinib versus furmonertinib for the first-line treatment of EGFR-Mutated combined MET-Positive unresectable locally advanced or recurrent metastatic NSCLC [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06962865"},{"key":"e_1_3_5_75_1","unstructured":"An Open-label randomized controlled Phase 3 study of Sigvotatug vedotin in combination with Pembrolizumab compared with Pembrolizumab monotherapy as first-line treatment in participants with PD-L1 high (\u226550% of tumor cells expressing PD-L1) locally advanced unresectable or metastatic non-small cell lung cancer (BE6A LUNG-02). Internet. 2024 [cited 2026 Mar]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06758401"},{"key":"e_1_3_5_76_1","unstructured":"A Phase Ib\/II clinical study to evaluate the safety tolerability and efficacy of HLX43 (anti-PD-L1 ADC) in combination with serplulimab (anti-PD-1\u00a0humanized monoclonal antibody) in patients with advanced\/metastatic solid tumors [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06848699"},{"key":"e_1_3_5_77_1","unstructured":"A Phase 1\/2 study of REGN5093-M114 (METxMET antibody-drug conjugate) in patients with MET overexpressing advanced cancer [Internet]. 2021 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04982224"},{"key":"e_1_3_5_78_1","unstructured":"Phase II trial: photoimmunotherapy and anti-PD1 in patients with refractory inoperable and metastatic non-Small cell lung cancer [Internet]. 2025 [cited 2026 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06943664"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.32752"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2021"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.129"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01509-2"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf228"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101997"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1155\/ecc\/6518713"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.10.016"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31090422"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425617"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03261-y"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17121581"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090582"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae151"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(25)00196-0"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2706715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2706715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2706715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:18:56Z","timestamp":1786699136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2706715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14712598.2026.2706715"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2706715","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}